Merck KGaA, Darmstadt, Germany, raises forecast for full year 2021

Disclosure of inside information pursuant to Article 17 of the Regulation (EU) No 596/2014

03 Nov 2021 | Darmstadt, Germany

Today, Merck KGaA, Darmstadt, Germany, has published the following ad hoc news:

Based on a very strong third quarter of 2021 with net sales of EUR 4.97 bn resulting in EBITDA pre1 of EUR 1.55 bn and EPS pre1 of EUR 2.24, Merck KGaA, Darmstadt, Germany, (the “Company”) has further raised its forecast for the entire group for fiscal 2021. The main driver is a very strong operating performance from the Life Science business sector. The Company now projects net sales of approx. EUR 19.30 – 19.85 bn (previously EUR 18.80 – 19.70 bn). EBITDA pre1 is anticipated to grow to approx. EUR 6.0 – 6.3 bn for the group (previously “EUR 5.6 – 6.0 bn”). EPS pre1 is projected to amount to approx. EUR 8.50 – 9.00 (previously “EUR 7.80 – 8.50”).

The Company will publish Q3 / 2021 figures as scheduled on 11 November 2021.

 

Downloads

For more information please contact Andreas Cezanne

1 EBITDA pre and EPS pre are alternative performance measures not defined by international accounting standards, used by the Company to improve the comparability of business performance over time and within the industry. EBITDA pre means earnings before interest, income tax, depreciation and amortization as well as adjustments (Ergebnis vor Zinsen, Ertragsteuern, Abschreibungen und Anpassungen). EPS pre means profit after tax including adjustments per theoretical shares outstanding (see Merck KGaA, Darmstadt, Germany, Annual Report 2020).

 

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck KGaA, Darmstadt, Germany, generated sales of € 17.5 billion in 66 countries.

The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Related News

  1. Press Releases

    Merck KGaA, Darmstadt, Germany Highlights Novel Mechanisms with the Potential ...

    Merck KGaA, Darmstadt, Germany, today provided an overview of its innovative pipeline with a focus on five mid- to late-stage assets with first-in-class and/or best-in-class potential at its R&D Update Call.

    2021/11/22